Brainsway (BWAY) EBITDA Margin (2018 - 2026)
Brainsway (BWAY) posted quarterly EBITDA Margin of 18.11% for Q1 2026, up 688.0% year-on-year from 2.3% in Q1 2025, and up 14.95% on a QoQ basis from 15.75% in Q4 2025.
Brainsway (BWAY) EBITDA Margin (2018 - 2026) Analysis & Trends
Brainsway (BWAY) has reported EBITDA Margin for 9 consecutive years, with 18.11% the latest figure, recorded in Q1 2026.
- Quarterly EBITDA Margin rose 688.0% year-over-year to 18.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 15.25% (up 337.0% YoY) and the FY2025 annual result came in at 13.51%, up 234.0% from the prior year.
- EBITDA Margin climbed to 18.11% in Q1 2026 per BWAY's latest filing, from 15.75% in the prior quarter.
- Over the last five years, EBITDA Margin for BWAY reached as high as 18.11% in Q1 2026 and fell as low as 79.86% in Q3 2022.
- A 5-year average of 5.68% and a median of 8.38% in 2023 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 6456 bps — and 2023, when it jumped 8400 bps.
- Year by year, EBITDA Margin stood at 60.14% in 2022, then jumped by 114 bps to 8.38% in 2023, then soared by 57 bps to 13.16% in 2024, then increased by 20 bps to 15.75% in 2025, then climbed by 15 bps to 18.11% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 18.11%, 15.75%, and 14.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Brainsway | 646.63 Mn | 587.74 Mn | 11.68 Mn | 18.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.11% |
| Dec 31, 2025 | 15.75% |
| Sep 30, 2025 | 14.96% |
| Jun 30, 2025 | 11.49% |
| Mar 31, 2025 | 11.23% |
| Dec 31, 2024 | 13.16% |
| Sep 30, 2024 | 10.64% |
| Jun 30, 2024 | 12.47% |
| Mar 31, 2024 | 7.86% |
| Dec 31, 2023 | 8.38% |
| Sep 30, 2023 | 4.14% |
| Jun 30, 2023 | -8.09% |
| Mar 31, 2023 | -43.12% |
| Dec 31, 2022 | -60.14% |
| Sep 30, 2022 | -79.86% |
| Jun 30, 2022 | -14.99% |
| Mar 31, 2022 | -18.59% |
| Dec 31, 2021 | -17.14% |
| Sep 30, 2021 | -15.30% |
| Jun 30, 2021 | -21.60% |